{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:28:46Z","timestamp":1752283726496},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jash.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T20:15:59Z","timestamp":1456344959000},"page":"282-284","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is there a preferred diuretic class for patients with renal impairment and hypertension?"],"prefix":"10.1016","volume":"10","author":[{"suffix":"Jr.","given":"Joseph L.","family":"Izzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon W.","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2016.02.008_bib1","first-page":"S118","article-title":"A history of edema and its management","volume":"59","author":"Eknoyan","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jash.2016.02.008_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/01.HYP.32.6.1071","article-title":"Thiazide-induced vasodilation in humans is mediated by potassium channel activation","volume":"32","author":"Pickkers","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.02.008_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-pharmtox-010814-124446","article-title":"Intraclass differences among antihypertensive drugs","volume":"55","author":"Feldman","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jash.2016.02.008_bib4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jash.2016.02.008_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2016.02.008_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2016.02.008_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.hfc.2011.11.001","article-title":"The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology\/American Heart Association stage B heart failure","volume":"8","author":"Pitt","year":"2012","journal-title":"Heart Failure Clin"},{"key":"10.1016\/j.jash.2016.02.008_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1751-7176.2012.00614.x","article-title":"Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and renin-angiotensin-aldosterone blockade","volume":"14","author":"Izzo","year":"2012","journal-title":"J Clin Hypertens"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T22:57:21Z","timestamp":1536965841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171116000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1933171116000905"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2016.02.008","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a preferred diuretic class for patients with renal impairment and hypertension?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2016.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}